Enterobacteriaceae infections are caused by Enterobacter species, pathogens responsible for causing severe infections including bacteremia, urinary tract infections, lower respiratory tract infections, skin and soft tissue infections, and intra-abdominal infections.
This report contains market size and forecasts of Enterobacteriaceae Infection Drug in Global, including the following market information:
Global Enterobacteriaceae Infection Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Enterobacteriaceae Infection Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Beta-lactams Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Enterobacteriaceae Infection Drug include Genentech, Nanotherapeutics, Novartis, Pfizer, Nymox Pharmaceutical, Sequoia Sciences, Phico Therapeutics and Cantab Biopharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Enterobacteriaceae Infection Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Enterobacteriaceae Infection Drug Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Enterobacteriaceae Infection Drug Market Segment Percentages, by Type, 2021 (%)
Beta-lactams Drugs
Carbapenems Drugs
Fluoroquinolones Drugs
Others
Global Enterobacteriaceae Infection Drug Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Enterobacteriaceae Infection Drug Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Enterobacteriaceae Infection Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Enterobacteriaceae Infection Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Enterobacteriaceae Infection Drug revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Enterobacteriaceae Infection Drug revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Genentech
Nanotherapeutics
Novartis
Pfizer
Nymox Pharmaceutical
Sequoia Sciences
Phico Therapeutics
Cantab Biopharmaceuticals